In an interview on ‘Money Movers’, Novartis CEO Vas Narasimhan provided insights into the factors underpinning the company’s robust financial guidance and acknowledged the potential for friction in U.S. pricing. Narasimhan highlighted the company’s focus on innovative therapies and its commitment to delivering value to patients. He also discussed the competitive dynamics in the pharmaceutical industry and emphasized the importance of collaboration and partnerships in driving growth. Additionally, he addressed the company’s efforts to control costs and improve operational efficiency while maintaining its investment in research and development.
Novartis CEO Vas Narasimhan Discusses Company’s Strong Guidance on ‘Money Movers’
